ChronoScale Corporation Common Stock (CHRN) Stock Price, News & Analysis

Company Overview

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions. These devices are utilized in hospitals and rehabilitation centers across North America and Europe, enabling physical therapists to deliver overground gait training with customizable robotic support and integrated performance tracking.

On the industrial side, EksoWorks exoskeletons—including the EksoVest and EksoZeroG—help reduce workplace fatigue and lower the risk of musculoskeletal injuries in manufacturing, warehousing and automotive assembly. By offloading weight and supporting the arms or torso, these wearable solutions improve ergonomics, enhance worker safety and boost productivity in environments that involve repetitive overhead or lifting tasks.

Ekso Bionics serves a global customer base spanning the United States, Europe and Asia. The company’s leadership team, led by Chief Executive Officer Paul R. Sandner, brings together expertise in robotics, biomechanics and healthcare to drive ongoing innovation and expand market adoption of wearable robotics technologies.

Key Stats

• Today's Range: $16.50 to $18.47
• 50-Day Range: $8.02 to $18.36
• 52-Week Range: $2.73 to $20.70
• Volume: 260,428 shs
• Average Volume: 384,741 shs
• Market Capitalization: $60.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Reduce

ChronoScale Corporation Common Stock Stock Analysis - MarketRank™

ChronoScale Corporation Common Stock scored higher than 25% of companies evaluated by MarketBeat, and ranked 780th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

ChronoScale Corporation Common Stock has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Downside Risk

ChronoScale Corporation Common Stock has a consensus price target of $6.00, representing about 64.6% downside from its current price of $16.97.

Amount of Analyst Coverage

ChronoScale Corporation Common Stock has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ChronoScale Corporation Common Stock are expected to grow in the coming year, from ($0.10) to ($0.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ChronoScale Corporation Common Stock is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ChronoScale Corporation Common Stock is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ChronoScale Corporation Common Stock has a P/B Ratio of 4.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.79% of the float of ChronoScale Corporation Common Stock has been sold short.

Short Interest Ratio / Days to Cover

ChronoScale Corporation Common Stock has a short interest ratio ("days to cover") of 1.01, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ChronoScale Corporation Common Stock has recently increased by 135.08%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ChronoScale Corporation Common Stock does not currently pay a dividend.

Dividend Growth

ChronoScale Corporation Common Stock does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.29

News Sentiment

ChronoScale Corporation Common Stock has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for ChronoScale Corporation Common Stock this week, compared to 2 articles on an average week.

Search Interest

20 people have searched for CHRN on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added ChronoScale Corporation Common Stock to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 3.2 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $15,500.00 in company stock, which represents 0.0256% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, ChronoScale Corporation Common Stock insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,500.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

6.90% of the stock of ChronoScale Corporation Common Stock is held by insiders.

Percentage Held by Institutions

6.42% of the stock of ChronoScale Corporation Common Stock is held by institutions.

Company Calendar

• Last Earnings: 4/28/2026
• Today: 6/02/2026
• Next Earnings (Estimated): 7/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Machinery
• Current Symbol: NASDAQ:CHRN
• Previous Symbol: NASDAQ:EKSO
• CIK: 1549084
• Web: www.eksobionics.com
• Phone: 510-984-1761
• Fax: 510-927-2647
• Employees: 60
• Year Founded: 2005

Price Target and Rating

• Average Price Target for ChronoScale Corporation Common Stock: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: -64.6%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.69 million
• Net Margins: -135.66%
• Pretax Margin: -135.66%
• Return on Equity: -197.81%
• Return on Assets: -74.17%

Debt

• Debt-to-Equity Ratio: 0.25
• Current Ratio: 1.55
• Quick Ratio: 1.03

Sales & Book Value

• Annual Sales: $84.38 million
• Price / Sales: 0.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.44 per share
• Price / Book: 4.93

Miscellaneous

• Outstanding Shares: 3,563,000
• Free Float: 3,317,000
• Market Cap: $60.46 million
• Optionable: No Data
• Beta: 0.86